Humanized monoclonal antibody that binds IgE to prevent its binding to the high affinity IgE receptor and blocking IgE mediated allergic response and inflammation in Bronchial Asthma is:
An anti-IgE preparation, Omalizumab, is approved by the FDA for use as an add-on therapy in children >=12 yr who have moderate to severe allergic asthma that is difficult to control.
Palivizumab
Natalizumab
Omalizumab
Etilizumab
Other Respiratory Disorders